Absci Corporation (ABSI)
NASDAQ: ABSI · IEX Real-Time Price · USD
4.980
-0.210 (-4.05%)
At close: May 2, 2024, 4:00 PM
4.990
+0.010 (0.20%)
After-hours: May 2, 2024, 7:55 PM EDT
Absci Revenue
In the year 2023, Absci had annual revenue of $5.72M, a decrease of -0.50%. Revenue in the quarter ending December 31, 2023 was $338.00K, a -78.29% decrease year-over-year.
Revenue (ttm)
$5.72M
Revenue Growth
-0.50%
P/S Ratio
98.49
Revenue / Employee
$36,890
Employees
155
Market Cap
563.15M USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 5.72M | -29.00K | -0.50% |
| Dec 31, 2022 | 5.75M | 965.00K | 20.18% |
| Dec 31, 2021 | 4.78M | 2.00K | 0.04% |
| Dec 31, 2020 | 4.78M | 2.72M | 132.04% |
| Dec 31, 2019 | 2.06M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Cross Country Healthcare | 2.02B |
| Embecta | 1.12B |
| Accolade | 414.29M |
| SI-BONE | 138.89M |
| CureVac | 59.73M |
| Jin Medical International | 19.82M |
| IGM Biosciences | 2.13M |
ABSI News
- 6 weeks ago - Absci Reports Business Updates and Fourth Quarter and Full Year 2023 Financial and Operating Results - GlobeNewsWire
- 2 months ago - Absci Announces Closing of Public Offering of Common Stock Including Full Exercise of the Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 2 months ago - Absci Announces Pricing of Public Offering of Common Stock - GlobeNewsWire
- 2 months ago - Absci Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 2 months ago - Absci Initiates IND-Enabling Studies for ABS-101, a Potential Best-in-Class Anti-TL1A Antibody de novo Designed and Optimized Using Generative AI - GlobeNewsWire
- 4 months ago - Absci Appoints Professor Sir Mene Pangalos to its Board of Directors - GlobeNewsWire
- 4 months ago - Absci to Participate in the 26th Annual Needham Growth Conference - GlobeNewsWire
- 4 months ago - Absci to Participate in the 42nd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire